HCD Healthcare & Diagnostics
GermanyWho owns HCD Healthcare & Diagnostics?
HCD Healthcare & Diagnostics is a German Healthcare company, currently owned by capiton since 2022.
Hand-verified · updated 2026-07-03
Open JSON · CC-BY
More from capiton VI
Other portfolio companies in the same fund.
Switzerland
More PE-backed in Healthcare
Comparable healthcare deals from other GPs.
US
Questions
Who owns HCD Healthcare & Diagnostics?
HCD Healthcare & Diagnostics is currently owned by capiton, through capiton VI, since 2022.
When did capiton acquire HCD Healthcare & Diagnostics?
capiton acquired HCD Healthcare & Diagnostics in 2022.
About HCD Healthcare & Diagnostics
HCD Healthcare & Diagnostics is a Berlin-based medical diagnostics group that consolidates pathology and histology practices across Germany. The platform brings together medical practices at five German locations together with a hospital in Lower Saxony, and processes more than 120,000 samples per year according to its sponsor's disclosures. Its stated purpose is to support the shift toward outpatient diagnostic services within the German healthcare system, pooling laboratory capacity, procurement and administrative overhead across sites. Positioned in the fragmented German pathology market, HCD pursues scale through the acquisition and integration of independent practices.
Ownership journey
HCD Healthcare & Diagnostics was established in 2022 as a consolidation platform in the German diagnostics sector, headquartered in Berlin. The buy-and-build concept was created and backed by capiton, the German mid-market investment firm, through its capiton VI fund. In 2022 the platform was launched with the acquisition of a hospital in Lower Saxony and three medical practices in Northern Westphalia, forming the initial base for the group. capiton remains an active shareholder and HCD is still listed as a current portfolio company, with no exit or secondary transaction recorded.
Under PE ownership
Under capiton's ownership from 2022, HCD has been built as a dedicated buy-and-build platform, growing from an initial hospital and three practices into a group spanning five locations plus the Lower Saxony hospital. The investment thesis centers on inorganic growth, with successive practice acquisitions intended to add clinical capacity and geographic reach. Management targets synergies across the enlarged group, including procurement and overhead cost savings realized as sites are integrated onto shared infrastructure. Operationally the platform now handles more than 120,000 diagnostic samples annually, per sponsor disclosures, as it consolidates a fragmented segment of German pathology.